Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake

Executive Summary

Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.

You may also be interested in...



Keeping Track: Opdivo Dosing Simplified; Yosprala, Cuvitru Approved; Telotristat Review Lengthened

The latest drug development news and highlights from our FDA Performance Tracker.

Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances

As with Purdue’s Targiniq, agency requires a post-marketing study to determine whether the new morphine/naltrexone formulation actually deters abuse.

Can FDA Finally Put Its Zohydro Problem Behind It?

FDA sees progress on the opioid front with Zogenix and Teva the latest to seek abuse-deterrence claims, but is the existing science able to adequately fight abuse?

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel